© 1996 Oxford University Press
research-article |
Atrial Fibrillation and Stroke Prevention in the Community
1Elderly Care Directorate, South Tyneside District Hospital South Shields, Tyne and Wear NE34 0PL
2Queen Elizabeth Hospital Gateshead NE9 6SX
Atrial fibrillation (AF) is an important and independent risk factor for stroke, particularly in elderly people. The efficacy of treatment with warfarin and aspirin in primary and secondary stroke prevention in AF has been demonstrated in randomized clinical trials. In a demographic study, we examined the prevalence of AF in patients registered with a general practice in the North East of England; 91 patients with known AF were identified, 69 with chronic AF and 22 with paroxysmal AF. The mean duration of the arrhythmia was 6.43 years and the prevalence of AF increased with age. There was a high prevalence of cerebrovascular disease in AF patients. The majority of AF patients were not receiving therapy with aspirin or warfarin as primary or secondary stroke prevention. If strategies for stroke prevention in AF are to be applied to the community, general practitioners will need to play a more active part.0
Revision received December 18, 1995.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Sappok, A. Faulstich, E. Stuckert, H. Kruck, P. Marx, and H.-C. Koennecke Compliance With Secondary Prevention of Ischemic Stroke: A Prospective Evaluation Stroke, August 1, 2001; 32(8): 1884 - 1889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hillen, R. Dundas, E. Lawrence, J. A. Stewart, A. G. Rudd, and C. D. A. Wolfe Antithrombotic and Antihypertensive Management 3 Months After Ischemic Stroke : A Prospective Study in an Inner City Population Stroke, February 1, 2000; 31(2): 469 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Bungard, W. A. Ghali, K. K. Teo, F. A. McAlister, and R. T. Tsuyuki Why Do Patients With Atrial Fibrillation Not Receive Warfarin? Arch Intern Med, January 10, 2000; 160(1): 41 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Hart, L. A. Pearce, R. M. Rothbart, J. H. McAnulty, R. W. Asinger, J. L. Halperin, and for the Stroke Prevention in Atrial Fibrillation I Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy J. Am. Coll. Cardiol., January 1, 2000; 35(1): 183 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Howitt and D. Armstrong Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation BMJ, May 15, 1999; 318(7194): 1324 - 1327. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. E O'Connell, C. S Gray, J. M French, and I. H Robertson Atrial fibrillation and cognitive function: case-control study J. Neurol. Neurosurg. Psychiatry, September 1, 1998; 65(3): 386 - 389. [Abstract] [Full Text]
|
|
|
|
|
|
R. Thomson, H. McElroy, and M. Sudlow Guidelines on anticoagulant treatment in atrial fibrillation in Great Britain: variation in content and implications for treatment BMJ, February 14, 1998; 316(7130): 509 - 513. [Abstract] [Full Text]
|
|
|
|
|
|
L. Kalra, I. Perez, and A. Melbourn Stroke Risk Management : Changes in Mainstream Practice Stroke, January 1, 1998; 29(1): 53 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F. Gillum and C. T. Sempos The End of the Long-term Decline in Stroke Mortality in the United States? Stroke, August 1, 1997; 28(8): 1527 - 1529. [Full Text]
|
|
|
|
 |
|
 R. J. Ackermann Anticoagulant Therapy in Patients Aged 80 Years or More With Atrial Fibrillation: More Caution Is Needed Arch Fam Med, March 1, 1997; 6(2): 105 - 110. [Abstract] [PDF]
|
|